Nov. 28th GreLonghu | Haitong Sec research reports pointed out that Remegen (688331.SH) performed well in the third quarter, with continuous revenue growth and narrowing losses. The growth is mainly attributed to the continuous increase in sales of core products RC18 and RC48, with RC18 SLE indications implementing new medical insurance prices this year, and RA indications approved for listing in July this year, expected to contribute incrementally. Multiple indications of the company's core products are in the late clinical stage, expected to be successively listed in the next two years to contribute incrementally. Giving it a 13-17 times PS for 2024, corresponding to a reasonable price range of 42.46-55.53 yuan, and rating it as "outperform the market".
研报掘金丨海通证券：予荣昌生物“优于大市”评级，核心产品的多个适应症处于临床后期
Research reports on the gold mine丨 Haitong sec: Assigned a 'better than the market' rating to remegen, with multiple indications of core products in the late clinical stage.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated